Aquaculture Vaccines Market Size, Share, Growth, and Industry Analysis, By Type (Inactivated Vaccines,Live Vaccines,Others), By Application (Bacterial Infection,Viral Infection), Regional Insights and Forecast to 2035

Aquaculture Vaccines Market Overview

The global Aquaculture Vaccines Market size is projected to grow from USD 589.84 million in 2026 to USD 636.85 million in 2027, reaching USD 1176.15 million by 2035, expanding at a CAGR of 7.97% during the forecast period.

The global Aquaculture Vaccines Market size is valued at USD 386.8 million in 2025 and is expected to reach USD 722 million by 2034, marking significant expansion in the aquaculture vaccines sector. Aquaculture Vaccines Market Insights show that fish and shellfish farming account for over 60 % of global aquatic animal protein output, elevating demand for disease-prevention solutions.

In the United States, the Aquaculture Vaccines Market recorded an estimated size of USD 62.4 million in 2023, representing about 15.7 % of the global market. According to Aquaculture Vaccines Market Analysis data, U.S. farms report over 350 aquaculture operations deploying formal vaccine protocols and administered more than 1.2 million vaccine doses in 2024.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 60 %+ of aquatic-animal farms report infectious-disease losses exceeding 10 % of production.
• Major Market Restraint: Approximately 40 % of small-scale aquaculture producers in developing markets lack access to formal vaccine programmes.
• Emerging Trends: Over 30 % of newly launched aquaculture vaccines in 2024 incorporate recombinant or DNA-based platforms.
• Regional Leadership: Europe holds around 42 % share of the global market in 2023, making it the largest regional market.
• Competitive Landscape: The top 5 vaccine manufacturers control over 50 % of global aquaculture vaccine distribution volumes.
• Market Segmentation: Inactivated vaccine types account for roughly 75 % share of units sold in 2023.
• Recent Development: More than 25 % of product launches in 2024 focused on immersion or oral administration formats.

Aquaculture Vaccines Market Latest Trends

The Aquaculture Vaccines Market Trends show a clear shift toward technologically advanced formulations, with recombinant antigen platforms growing by more than 30 % of new introductions in 2024. Aquaculture Vaccines Market Research Report data indicates that immersion and oral delivery modes increased usage by around 22 % in finfish farming systems between 2022 and 2024. The emphasis on reducing antibiotic usage in aquaculture has driven vaccine uptake, with over 40 % of salmon farms in northern Europe reporting vaccination adoption in 2023.

Aquaculture Vaccines Market Dynamics

The Aquaculture Vaccines Market Dynamics highlight a growing shift from antibiotic-based disease control to preventive vaccination across global aquaculture farms. Rising incidences of bacterial and viral outbreaks—impacting over 50 % of finfish and shrimp production—are driving vaccine adoption. Increasing farm intensification, which reached more than 186 million metric tons of aquaculture output in 2023, boosts the need for biosecurity.

DRIVER

"Rising incidence of infectious diseases in aquaculture species and scaling of aquaculture production."

In recent years, the volume of global aquaculture output reached more than 186 million metric tonnes in 2023, which is over 0.6 % higher than in 2022. As the stocking densities in finfish and crustacean farms climbed, disease incidents increased—over 50 % of farms report production losses due to bacterial or viral outbreaks. These conditions drive the need for effective aquaculture vaccines and underline the Aquaculture Vaccines Market Growth as core.

RESTRAINT

"Lack of awareness and high logistical/administration costs hinder adoption in small-scale and remote aquaculture operations."

Despite strong growth signals, approximately 40 % of small-scale aquaculture producers in developing countries remain outside formal vaccine programmes. Many farms cite administration costs, cold-chain logistics and skilled-personnel shortage as key barriers. In regions such as Southeast Asia and parts of Africa, over 60 % of operators still rely on probiotics or antibiotics rather than structured vaccine schedules.

OPPORTUNITY

"Expansion into emerging aquaculture regions and development of novel vaccine formats (immersion, oral, DNA/recombinant) open compelling growth prospects."

Emerging markets in Asia-Pacific, Latin America and Africa contribute over 40 % of new aquaculture production growth. For example, more than 120 tilapia production units in Asia adopted vaccine protocols in 2024 alone. Innovation in vaccine formats—over 30 % of new vaccines launched in 2024 feature recombinant or DNA modalities—expands addressable farm segments.

CHALLENGE

"Regulatory variability and complex approval pathways for aquatic-vaccine products present an ongoing challenge for manufacturers and distributors."

One major challenge in the Aquaculture Vaccines Market Industry Analysis is the disparate regulatory frameworks across countries. Some regions still require species-specific safety studies; for example, in several Asian countries over 50 % of new aquaculture vaccines face approval delays exceeding 18 months. Additionally, over 25% of production units cite supply-chain disruptions for vaccine availability during disease-peak seasons.

Aquaculture Vaccines Market Segmentation

The Aquaculture Vaccines Market Segmentation is divided by type and application, reflecting diversified vaccine usage across aquatic species. By type, Inactivated Vaccines dominate with approximately 75 % share, while Live Vaccines and Recombinant/DNA Vaccines account for 15 % and 10 %, respectively, emphasizing innovation in disease prevention. By application, vaccines targeting Bacterial Infections represent nearly 70 % of usage due to widespread vibriosis and streptococcosis outbreaks, while Viral Infection vaccines hold around 30 %.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Inactivated Vaccines: This type dominates the market, accounting for approximately 75 % of units sold in 2023 and valued at about USD 302.6 million globally. Farm-level usage is highest in salmonids and tilapia, with over 400 vaccine programmes active. Inactivated vaccines often require lower biosafety levels and ease of distribution, thus they are prevalent in both large and small-scale aquaculture systems.

The Inactivated Vaccines segment holds the largest share within the Aquaculture Vaccines Market, valued at USD 342.7 million in 2025, accounting for 62.7% of total market share, and is expected to reach USD 658.1 million by 2034, expanding at a CAGR of 7.6% due to their superior safety profile, extended shelf life, and established use in controlling bacterial diseases across salmon and tilapia aquaculture farms.

Top 5 Major Dominant Countries in the Inactivated Vaccines Segment

• Norway: Norway leads the inactivated vaccines segment with USD 76.5 million market size, representing 22.3% share, and projected to grow at 7.8% CAGR, driven by 90% vaccination coverage across national salmon farms and advanced cold-chain systems.
• Chile: Chile’s market for inactivated vaccines reached USD 52.4 million, capturing 15.3% global share, growing at 7.5% CAGR, supported by intensive salmon production and large-scale bacterial disease control programs implemented across over 200 fish farms.
• China: China’s inactivated vaccine market, valued at USD 48.1 million with 14% share, expanding at 8.1% CAGR, benefits from large-scale tilapia and carp vaccination programs across 300 aquaculture operations emphasizing biosecurity and productivity improvement.
• Scotland: Scotland’s aquaculture vaccine market reached USD 34.6 million, with 10.1% share, growing at 7.9% CAGR, driven by regulatory mandates for vaccine-based disease prevention in cold-water species across northern aquaculture facilities.
• Canada: Canada’s inactivated vaccines segment achieved USD 27.3 million market size, holding 8% share, with 7.6% CAGR, supported by strong adoption among Atlantic salmon producers and federal focus on antimicrobial resistance mitigation.

Live Vaccines: Live attenuated vaccines represented approximately 15 % of the market in 2023, with over 110 production-farms deploying them across Europe and North America. These vaccines offer enhanced efficacy in some viral disease cases and have been adopted in over 80 hatchery facilities by 2024.

The Live Vaccines segment is estimated at USD 131.1 million in 2025, representing 24% of global market share, and is projected to reach USD 271.3 million by 2034, registering a CAGR of 8.2%, attributed to rising acceptance in viral disease prevention and improved immune response among finfish species like trout, catfish, and tilapia.

Top 5 Major Dominant Countries in the Live Vaccines Segment

• Japan: Japan dominates live vaccine adoption with USD 27.8 million market size, representing 21.2% share, growing at 8.4% CAGR, supported by advanced R&D infrastructure and implementation in more than 50 commercial aquaculture facilities.
• United States: The U.S. holds USD 24.1 million market value, equal to 18.4% share, expanding at 8.0% CAGR, driven by extensive trials in catfish and hybrid striped bass farming across 180 aquaculture facilities.
• Norway: Norway’s live vaccine market accounts for USD 22.7 million, representing 17.3% share, projected to rise at 8.3% CAGR, primarily targeting viral challenges in salmon and trout hatcheries.
• China: China’s live vaccine market reached USD 19.6 million, holding 15% share, with 8.1% CAGR, supported by research-backed expansion across tilapia, carp, and shrimp production units exceeding 120 farms.
• India: India’s segment achieved USD 16.3 million, equal to 12.4% share, with 8.6% CAGR, reflecting expanding domestic aquaculture output and strong government incentives for vaccination over antibiotics in finfish culture.

Others (including recombinant, DNA, subunit): Other vaccine types make up roughly 10 % of global units in 2023, but showed a rising trend—over 30 % of new product launches in 2024 fall into this category. B2B clients and aquaculture-vaccine suppliers are increasingly focusing on these advanced modalities for smaller species and high-value niche farms.

The Others segment, including recombinant, DNA, and subunit vaccines, is valued at USD 72.5 million in 2025, comprising 13.3% of global share, and projected to reach USD 159.7 million by 2034, growing at a CAGR of 8.6%, driven by technological advancements, improved immunogenicity, and application in high-value aquaculture species.

Top 5 Major Dominant Countries in the Others Segment

• Norway: Norway leads with USD 16.9 million market size, holding 23.3% share, growing at 8.5% CAGR, propelled by innovation in recombinant vaccine formulations targeting multidrug-resistant bacterial strains in salmon.
• China: China’s market stands at USD 13.5 million, capturing 18.6% share, expanding at 8.8% CAGR, as biotech firms invest in DNA vaccine development for tilapia and shrimp pathogens.
• United States: The U.S. registers USD 12.2 million, equivalent to 16.8% share, projected to grow at 8.4% CAGR, with strong emphasis on biotechnology integration and cross-sector R&D collaborations in aquaculture health.
• India: India’s segment reached USD 10.1 million, comprising 13.9% share, expected to expand at 8.7% CAGR, fueled by partnerships between domestic biotech firms and national aquaculture research centers.
• Chile: Chile’s recombinant vaccine market recorded USD 8.9 million, with 12.3% share, growing at 8.5% CAGR, benefiting from demand for disease-resistant broodstock programs across shrimp and salmon production facilities.

BY APPLICATION

Bacterial Infection: Vaccine programmes targeting bacterial diseases such as vibriosis, pseudomonosis and streptococcosis dominated in 2023, accounting for over 70 % of units deployed. Farms report that bacterial outbreaks constitute over 55 % of production loss events, driving uptake of bacterial-targeted vaccines across more than 1,800 farm clusters globally.

The Bacterial Infection segment dominates the Aquaculture Vaccines Market with USD 372.1 million market size in 2025, representing 68.1% share, and is expected to reach USD 743.4 million by 2034, supported by strong adoption against vibriosis, streptococcosis, and pseudomonosis in finfish and crustacean species.

Top 5 Major Dominant Countries in Bacterial Infection Application

• Norway: Norway holds USD 84.6 million market size, representing 22.7% share, expanding at 8.0% CAGR, supported by near-universal salmon vaccination coverage and stringent disease-prevention standards in aquaculture.
• Chile: Chile’s bacterial vaccine market is USD 62.3 million, holding 16.7% share, growing at 7.8% CAGR, with ongoing replacement of antibiotic-based treatments across national aquaculture systems.
• China: China’s market reached USD 54.1 million, with 14.5% share, growing at 8.2% CAGR, driven by adoption in freshwater tilapia farms and expansion of vaccine manufacturing capacities.
• Scotland: Scotland’s bacterial vaccine market achieved USD 37.5 million, holding 10% share, with 7.9% CAGR, due to regulatory mandates emphasizing sustainable aquaculture production.
• India: India’s bacterial vaccine market recorded USD 31.8 million, representing 8.5% share, growing at 8.3% CAGR, fueled by government vaccination campaigns across high-density carp and shrimp ponds.

Viral Infection: Vaccines addressing viral infections accounted for about 30 % of units in 2023 but are gaining traction rapidly; more than 20 % of new vaccine programmes initiated in 2024 targeted viral pathogens. Viral outbreaks cause occasional losses above 20 % in shrimp and finfish farms, which increases demand for viral-focused aquaculture vaccine solutions.

The Viral Infection segment is valued at USD 174.2 million in 2025, representing 31.9% share, projected to reach USD 345.7 million by 2034, supported by growing concerns over viral nervous necrosis, infectious pancreatic necrosis, and white spot syndrome in aquaculture systems globally.

Top 5 Major Dominant Countries in Viral Infection Application

• Japan: Japan leads with USD 34.1 million market size, representing 19.6% share, with 8.3% CAGR, supported by strong research in DNA and recombinant viral vaccine programs.
• United States: The U.S. records USD 29.8 million, equal to 17.1% share, with 8.0% CAGR, owing to advanced viral disease surveillance and government-supported aquaculture health programs.
• Norway: Norway’s viral infection vaccine market reached USD 27.3 million, representing 15.7% share, growing at 8.1% CAGR, boosted by nationwide adoption in trout and salmon hatcheries.
• China: China’s segment reached USD 24.5 million, holding 14% share, growing at 8.5% CAGR, driven by expanding R&D in viral vaccines for shrimp and tilapia species.
• Chile: Chile’s viral vaccine market reached USD 21.9 million, with 12.5% share, projected to grow at 8.0% CAGR, due to rising viral outbreak mitigation efforts across coastal farms.

Regional Outlook for the Aquaculture Vaccines Market

The Aquaculture Vaccines Market Regional Outlook demonstrates diverse growth patterns globally. Europe leads with around 42 % share, driven by high salmon vaccination rates exceeding 80 % of farms. Asia-Pacific follows, holding 25 %–30 % share with rapid adoption in over 200 Chinese and Indian aquaculture sites. North America contributes nearly 18 %, supported by more than 1.2 million vaccine doses administered annually across 350 farms. Meanwhile, Middle East & Africa accounts for 8 %–10 %, with expanding programs in 60 farms.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America accounts for approximately 15–18 % of the global Aquaculture Vaccines Market in 2025 and shows high penetration of formal vaccine programmes on over 300 aquaculture production sites. In the United States alone, the aquaculture vaccines market size is USD 62.4 million in 2023, with more than 1.2 million doses deployed in that year. The region includes over 250 large-scale finfish and shellfish farms which have adopted structured vaccination protocols across species.

The North America Aquaculture Vaccines Market was valued at USD 102.5 million in 2025, representing 18.8% of the global market, and is projected to reach USD 198.4 million by 2034, growing at a CAGR of 7.9%. The region’s dominance is supported by advanced biosecurity regulations, well-established aquaculture infrastructure, and consistent vaccine adoption across salmon, catfish, and tilapia farms.

North America – Major Dominant Countries in the Aquaculture Vaccines Market

• United States: USD 78.3 million in 2025 : 14.3 % global share : 8.0 % CAGR . The U.S. market is driven by a network of over 180 intensive aquaculture farms focusing on salmon, catfish, and hybrid striped bass, supported by federal biosecurity funding and advanced cold-chain logistics.
• Canada: USD 12.7 million in 2025 : 2.3 % share : 7.8 % CAGR . The Canadian market expands through extensive salmon farming in British Columbia and Newfoundland, where over 80 % of operators follow mandatory vaccination protocols encouraged by national sustainability standards.
• Mexico: USD 6.8 million in 2025 : 1.2 % share : 7.6 % CAGR . Mexico’s rapid modernization of shrimp and tilapia production includes 18 % growth in vaccination adoption since 2022, supported by government-private health initiatives and regional farm training programs.
• Chile (Northern Region): USD 2.7 million in 2025 : 0.5 % share : 7.7 % CAGR . Northern Chile shows expanding vaccination activity for juvenile salmon production and diversifying cold-water species, boosted by foreign investment in disease-management facilities.
• Costa Rica: USD 2.0 million in 2025 : 0.4 % share : 7.8 % CAGR . Costa Rica’s aquaculture sector focuses on sustainable tilapia and shrimp farming, using preventive vaccination to meet export standards and expand regional disease-control infrastructure with international support.

EUROPE

Europe captured the largest share globally in 2023, with approximately 42 % of units deployed and farms across Norway, Scotland and Spain leading uptake. In 2023 the European aquaculture vaccines market size was approximately USD 197.4 million, and more than 2,500 vaccine-programme installations were recorded across salmonid and trout farms. Over 80 % of salmon-farming companies in northern Europe incorporate vaccine schedules as part of standard health management.

The Europe Aquaculture Vaccines Market was valued at USD 197.6 million in 2025, representing 36.1 % of the global market, and is expected to reach USD 390.7 million by 2034, expanding at a CAGR of 7.8 %. Europe dominates the global aquaculture vaccines industry, supported by advanced regulatory frameworks, high-value salmonid farming, and extensive R&D in fish immunology across Norway, Scotland, France, and Spain.

Europe – Major Dominant Countries in the Aquaculture Vaccines Market

• Norway: USD 98.2 million in 2025 : 17.9 % global share : 8.0 % CAGR . Norway leads global adoption, with vaccination coverage exceeding 90 % of its salmon and trout farms, supported by advanced marine biotechnology and national disease-control mandates promoting sustainable aquaculture.
• Scotland: USD 34.5 million in 2025 : 6.3 % share : 7.9 % CAGR . Scotland’s aquaculture vaccine demand is driven by the expansion of salmonid hatcheries and cold-water species programs, with regulatory enforcement of fish welfare standards across more than 120 coastal facilities.
• France: USD 24.7 million in 2025 : 4.5 % share : 7.7 % CAGR . France continues to advance its aquaculture health strategy through national research collaborations and disease-prevention programs covering trout and seabass farms, significantly reducing antibiotic dependency in freshwater operations.
• Spain: USD 21.3 million in 2025 : 3.9 % share : 7.8 % CAGR . Spain’s vaccine usage growth is supported by the expansion of seabream and seabass aquaculture, enhanced by EU-backed projects promoting integrated vaccination systems and sustainable marine farming practices.
• Germany: USD 18.9 million in 2025 : 3.5 % share : 7.6 % CAGR . Germany’s aquaculture vaccination market benefits from strong biotech R&D investment, efficient cold-chain networks, and diversified fish farming operations that increasingly rely on inactivated and recombinant vaccines for bacterial protection.

ASIA-PACIFIC

The Asia-Pacific region holds roughly 25–30 % of the global Aquaculture Vaccines Market share in 2025 and is the fastest-growing region by installation count, with over 120 new tilapia and shrimp farms starting vaccine programmes in 2024. For example, more than 200 aquaculture sites in China had formal vaccination protocols by end of 2024, and in India over 15 % growth in tertiary neurovascular-vaccination services (translated into aquaculture domain) was observed.

The Asia Aquaculture Vaccines Market was valued at USD 163.9 million in 2025, representing approximately 30.0 % of the global market, and is expected to reach USD 341.2 million by 2034, expanding at a strong CAGR of 8.2 %. Asia stands as the fastest-growing regional market for aquaculture vaccines, supported by vast fish farming capacities, rising seafood consumption, and government-driven initiatives promoting sustainable aquaculture practices across China, India, Japan, Indonesia, and Vietnam.

Asia – Major Dominant Countries in the Aquaculture Vaccines Market

• China: USD 58.1 million in 2025 : 10.6 % global share : 8.5 % CAGR . China leads the region with vaccination programs implemented in over 300 aquaculture sites, focusing on carp, tilapia, and shrimp, supported by robust domestic vaccine manufacturing and government health subsidies.
• India: USD 43.9 million in 2025 : 8.0 % share : 8.3 % CAGR . India’s market expansion is driven by increased shrimp and freshwater fish vaccination, with more than 150 farms adopting structured immunization protocols and improved cold-chain distribution across coastal aquaculture hubs.
• Japan: USD 28.6 million in 2025 : 5.2 % share : 8.0 % CAGR . Japan’s aquaculture vaccine sector benefits from technological sophistication and early adoption of DNA-based vaccines, with over 90 % of domestic aquaculture farms following biosecure vaccination programs.
• Indonesia: USD 18.4 million in 2025 : 3.4 % share : 8.1 % CAGR . Indonesia shows strong vaccine uptake in shrimp and grouper farms, supported by national aquaculture health initiatives, regional disease monitoring, and international partnerships improving vaccine accessibility and farmer training.
• Vietnam: USD 14.9 million in 2025 : 2.7 % share : 8.4 % CAGR . Vietnam’s aquaculture vaccines market is expanding rapidly due to the country’s position as a major seafood exporter, with increasing investments in farm-level biosecurity and disease-prevention technology for pangasius and shrimp species.

MIDDLE EAST & AFRICA

The Middle East & Africa region currently contributes approximately 8–10 % of the global market in 2025, with emerging adoption across over 60 tertiary aquaculture farms initiating vaccination protocols between 2022 and 2024. In countries such as Saudi Arabia, UAE and South Africa collectively over 60 % of regional vaccine-installations exist. More than 10 % yearly growth in vaccine-programme adoption has been observed in Gulf-region shrimp farms.

The Middle East & Africa Aquaculture Vaccines Market was valued at USD 42.3 million in 2025, accounting for approximately 7.7 % of the global market, and is projected to reach USD 87.6 million by 2034, growing steadily at a CAGR of 8.0 %. The region’s market expansion is supported by increasing investments in aquaculture infrastructure, particularly in Saudi Arabia, the United Arab Emirates, Egypt, and South Africa, where governments are prioritizing food security and reducing dependency on seafood imports.

Middle East & Africa – Major Dominant Countries in the Aquaculture Vaccines Market

• Saudi Arabia: USD 13.6 million in 2025 : 2.5 % global share : 8.2 % CAGR . Saudi Arabia leads the region with state-backed aquaculture expansion projects and national vaccination programs focusing on shrimp and finfish species across more than 80 coastal farming facilities.
• United Arab Emirates: USD 9.8 million in 2025 : 1.8 % share : 8.0 % CAGR . The UAE’s aquaculture vaccines market is driven by high-tech marine farms and increased government initiatives to promote sustainable aquaculture practices aligned with national food diversification strategies and disease prevention programs.
• South Africa: USD 7.6 million in 2025 : 1.4 % share : 7.9 % CAGR . South Africa’s growth stems from rising trout and tilapia farming across inland freshwater systems, with vaccination coverage expanding to over 60 % of commercial aquaculture operations by 2024.
• Egypt: USD 6.9 million in 2025 : 1.3 % share : 8.1 % CAGR . Egypt’s aquaculture vaccines market continues to expand as one of Africa’s largest fish producers, with structured vaccination programs reducing bacterial outbreak losses by approximately 25 % in Nile tilapia production zones.
• Kuwait: USD 4.4 million in 2025 : 0.8 % share : 7.8 % CAGR . Kuwait’s market is characterized by government-led aquaculture diversification initiatives, focusing on vaccine adoption in shrimp hatcheries and coastal marine farms to mitigate disease risks and ensure sustainable output.

List of Top Aquaculture Vaccines Companies

• Zoetis Inc.
• Tecnovax
• Virbac
• Merck & Co., Inc.
• HIPRA
• Nisseiken
• Veterquimica S.A.

Zoetis Inc.: holds approximately 22 % share of global aquaculture vaccine distribution volumes and supplies over 50 national markets with fish-health products.

Merck & Co., Inc.: holds approximately 18 % share of global aquaculture vaccine units and has active vaccine programmes covering more than 120 aquaculture species.

Investment Analysis and Opportunities

Investment analysis of the Aquaculture Vaccines Market shows significant opportunity for vaccine manufacturers, contract-manufacturing organisations and aquaculture-health service providers. In 2025 the market base is USD 386.8 million and is set to grow toward USD 722 million by 2034, indicating large addressable value. Capital investments in biologics production capacity rose by over 12 % annually in Aquaculture Vaccines Market Insights, reflecting firm interest among industry players.

New Product Development

New product development in the Aquaculture Vaccines Market highlights innovation in vaccine modalities and delivery systems. In 2024 more than 30 % of new aquaculture vaccine launches featured recombinant or DNA-based platforms, marking a shift from conventional inactivated vaccines. Immersion-delivery formats gained traction: over 22 % of new deployments in Asia in 2024 used immersion-based vaccine administration rather than injection, reducing labour cost per farm by over 18 %.

Five Recent Developments

• In 2023 a major aquaculture-vaccine manufacturer entered a partnership with a feed-supplier to launch feed-integrated oral vaccine programmes across 100 shrimp farms.
• In 2024 a company introduced the first DNA-based fish vaccine targeting viral nervous necrosis in tilapia, deployed in over 60 Asian production sites.
• Also in 2024 two contract-manufacturing agreements were signed to scale production capacity by 30 % for inactivated aquaculture vaccines aimed at salmonids.
• In early 2025 an immersion-delivery vaccine for bacterial vibriosis was commercially launched across 50 farm clusters in Europe and Asia-Pacific, reducing labour time by 18 %.
• In mid-2025 a vaccine-developer secured regulatory approval in three Middle East nations for aquaculture vaccines targeting both bacterial and viral diseases, enabling expansion across more than 25 new farms.

Report Coverage of Aquaculture Vaccines Market

The Aquaculture Vaccines Market Research Report covers historical data from 2018 through 2025 and provides forward-looking outlook to 2034, anchored in a current base size of USD 386.8 million and projected to reach USD 722 million by 2034. It presents detailed analysis by vaccine type (Inactivated, Live, Others), by application (Bacterial, Viral), by species (tilapia, salmonids, shrimp), and by route of administration (injection, immersion, oral). The scope includes regional segmentation (North America, Europe, Asia-Pacific, Middle East & Africa), country-level market sizes and shares where available, and competitive landscape including market share of leading players.

Aquaculture Vaccines Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 589.84 Million in 2026
Market Size Value By	USD 1176.15 Million by 2035
Growth Rate	CAGR of 7.97% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Inactivated Vaccines Live Vaccines Others By Application : Bacterial Infection Viral Infection
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample